Aim: Our aim is to evaluate vascular risk factors and laboratory findings in patients treated with IV thrombolysis, to compare these parameters according to neurological findings scored by a National Institutes of Health Stroke Scale (NIHSS) at admission, after 7 days and to investigate the impact of these parameters on stroke severity and outcome at 3rd month.
Methods: We reviewed 53 consecutive acute ischemic stroke patients admitted within 0-4.5 h after stroke onset and treated with IV thrombolysis between 2014 March-2018 May. Patients with acute posterior circulation stroke, and who underwent endovascular intervention after thrombolysis were excluded. Demographic features, vascular risk factors, laboratory findings and hemorrhagic transformation, and NIHSS scores of patients at admission and after 7 days, and also 3rd month mRS scores were recorded.
Results: The mean age of patients was 64.79±12.26 and 60.37 % of them were male. Mean NIHSS score at admission was 10.60±5.16 and one week after IV r-tPA treatment, the mean score was 7.07±5.39. Hemorrhagic transformation was 18.9%. The male ratio was significantly higher in mild-moderate stroke group (p=0.008), the prevalence of hypertension, diabetes, hemorrhagic transformation and blood urea levels were also significantly higher in severe stroke group than mild-moderate group (p≤ 0.05). In addition neutrophil levels was higher in severe group, but not statistically significant. Creatine levels were significantly higher in the poor outcome group (NIHSS difference <6) after one week.
Conclusion: Female gender, hemorrhagic transformation and high neutrophil levels were found to have impact on stroke severity towards poor prognosis independently.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.